Categories: All postsCannabis

CannTrust Holdings could be next to strike deal with big tobacco or alcohol: Echelon

Licensed Producer CannTrust Holdings (CannTrust Holdings Stock Quote, Chart TSX:TRST) produced a solid second quarter, according to analyst Russell Stanley of Echelon Wealth Partners, who sees CannTrust as a prime candidate for partnership or acquisition by alcohol, pharmacy or tobacco companies looking to establish a presence in the fledgling recreational cannabis sector.

Last week, Vaughan, Ontario’s CannTrust reported its Q2 2018 earnings, with revenue of $9.1 million, a 99 per cent increase over last year’s second quarter, and posted positive net earnings for the fifth consecutive quarter.

“We are very pleased with our Q2 results. We continued to experience dynamic growth in all areas of the Company as we execute our business plan aimed at being a market leader and innovator in the development of products and services to better serve our patients and physicians and to position us for the October 17 legalization of the adult use recreational market,” CEO Eric Paul said.

Stanley views the quarterly results positively, noting that although revenue was slightly lower than his forecast of $9.4 million but better than the consensus of $9.0 million, TRST’s EBITDA loss was $1.6 million, which was better than his estimate of $1.9 million and matched the consensus. He says that the company’s EBITDA was below his forecast in each of the previous two quarters, making Q2’s results encouraging.

“Extracts/oils continue to be the fastest growing product category, with sales up 135 per cent year over year and 20 per cent quarter over quarter, overshadowing strong dried cannabis sales growth of 80 per cent year over year and 17 per cent quarter over quarter,” says Stanley in a note to clients last Thursday. “Extract/oil sales continue to represent 60 per cent of cannabis product revenue, and TRST continues to lead the industry on this metric.”

Stanley says last week’s deal by alcohol company Constellation Brands to increase its investment in sector leader Canopy Growth is further confirmation that “cannabis is a global market opportunity.”

“We expect M&A and strategic investment activity to heat up and we view CannTrust as a strong potential candidate for major players from any of the alcohol/pharmaceutical/tobacco/consumer packaged goods industries,” says the analyst. “On that basis, we are effectively increasing our valuation multiple by rolling forward from 17.5x EV/2019E EBITDA to 17.5x EV/2020E EBITDA.”

CannTrust Holdings stock a “Top Pick”

The analyst has trimmed his sales volume and EBITDA estimates for 2019 to reflect the potential lag in the ramp up of volumes in Ontario. He maintains his Top Pick and “Speculative Buy” ratings for TRST with the reiterated price target of $21.00, representing a projected return of 170 per cent at the time of publication.

Stanley says additional potential catalysts for TRST going forward include supply agreement announcements, GMP certification, international developments and its third quarter results due in November.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: trst
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago